Niveles de hemoglobina glicosilada y diferencia en el gasto en salud de pacientes diabéticos: un estudio econométrico

Background: Complications increase treatment costs of diabetes mellitus (DM). An adequate metabolic control of the disease could reduce these costs. Aim: To evaluate the costs of medical care for a cohort of patients with DM, according to their degree of metabolic compensation. Material and Methods:...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lenz,Rony, Zarate,Aldo, Rodríguez,Jorge, Ramírez,Jorge
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2014
Materias:	Diabetes mellitus Health care costs Hemoglobin A, glycosylated
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000700004
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872014000700004
record_format	dspace
spelling	oai:scielo:S0034-988720140007000042014-12-10Niveles de hemoglobina glicosilada y diferencia en el gasto en salud de pacientes diabéticos: un estudio econométricoLenz,RonyZarate,AldoRodríguez,JorgeRamírez,Jorge Diabetes mellitus Health care costs Hemoglobin A, glycosylated Background: Complications increase treatment costs of diabetes mellitus (DM). An adequate metabolic control of the disease could reduce these costs. Aim: To evaluate the costs of medical care for a cohort of patients with DM, according to their degree of metabolic compensation. Material and Methods: All diabetic patients attended in a regional hospital from 2005 to 2010 were analyzed. A correlational study between costs of individual healthcare and levels of glycosylated hemoglobin (HbA1c), was performed in a series of annual cross-sectional measurements. Results: The study comprised 1,644 diabetic patients. During the study period the average cost of healthcare per patient increased from $878,000 to more than $1,000,000 Chilean pesos (CLP) during the study period. The percentage of patients with HbA1c levels below 7.0% varied between 43.0% and 54.9%. Costs for patients with HbA1c levels between 7 and 8.9% were 1.3 to 1.5 times greater. For the group of patients with HbA1c levels between 9 and 10.9% the costs increased 1.4 to 1.6 times. For patients with HbA1c levels greater than 11.0%, healthcare costs doubled. Conclusions: Healthcare expenditure varied according to metabolic control, which is consistent with international findings. This study was limited by its selected population, incomplete information on health expenditures, and the inclusion of only direct costs to the health system. If all patients would achieve metabolic compensation, the yearly savings would be CLP $308,000,000 (or USD $657,000).info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.142 n.7 20142014-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000700004es10.4067/S0034-98872014000700004
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Diabetes mellitus Health care costs Hemoglobin A, glycosylated
spellingShingle	Diabetes mellitus Health care costs Hemoglobin A, glycosylated Lenz,Rony Zarate,Aldo Rodríguez,Jorge Ramírez,Jorge Niveles de hemoglobina glicosilada y diferencia en el gasto en salud de pacientes diabéticos: un estudio econométrico
description	Background: Complications increase treatment costs of diabetes mellitus (DM). An adequate metabolic control of the disease could reduce these costs. Aim: To evaluate the costs of medical care for a cohort of patients with DM, according to their degree of metabolic compensation. Material and Methods: All diabetic patients attended in a regional hospital from 2005 to 2010 were analyzed. A correlational study between costs of individual healthcare and levels of glycosylated hemoglobin (HbA1c), was performed in a series of annual cross-sectional measurements. Results: The study comprised 1,644 diabetic patients. During the study period the average cost of healthcare per patient increased from $878,000 to more than $1,000,000 Chilean pesos (CLP) during the study period. The percentage of patients with HbA1c levels below 7.0% varied between 43.0% and 54.9%. Costs for patients with HbA1c levels between 7 and 8.9% were 1.3 to 1.5 times greater. For the group of patients with HbA1c levels between 9 and 10.9% the costs increased 1.4 to 1.6 times. For patients with HbA1c levels greater than 11.0%, healthcare costs doubled. Conclusions: Healthcare expenditure varied according to metabolic control, which is consistent with international findings. This study was limited by its selected population, incomplete information on health expenditures, and the inclusion of only direct costs to the health system. If all patients would achieve metabolic compensation, the yearly savings would be CLP $308,000,000 (or USD $657,000).
author	Lenz,Rony Zarate,Aldo Rodríguez,Jorge Ramírez,Jorge
author_facet	Lenz,Rony Zarate,Aldo Rodríguez,Jorge Ramírez,Jorge
author_sort	Lenz,Rony
title	Niveles de hemoglobina glicosilada y diferencia en el gasto en salud de pacientes diabéticos: un estudio econométrico
title_short	Niveles de hemoglobina glicosilada y diferencia en el gasto en salud de pacientes diabéticos: un estudio econométrico
title_full	Niveles de hemoglobina glicosilada y diferencia en el gasto en salud de pacientes diabéticos: un estudio econométrico
title_fullStr	Niveles de hemoglobina glicosilada y diferencia en el gasto en salud de pacientes diabéticos: un estudio econométrico
title_full_unstemmed	Niveles de hemoglobina glicosilada y diferencia en el gasto en salud de pacientes diabéticos: un estudio econométrico
title_sort	niveles de hemoglobina glicosilada y diferencia en el gasto en salud de pacientes diabéticos: un estudio econométrico
publisher	Sociedad Médica de Santiago
publishDate	2014
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000700004
work_keys_str_mv	AT lenzrony nivelesdehemoglobinaglicosiladaydiferenciaenelgastoensaluddepacientesdiabeticosunestudioeconometrico AT zaratealdo nivelesdehemoglobinaglicosiladaydiferenciaenelgastoensaluddepacientesdiabeticosunestudioeconometrico AT rodriguezjorge nivelesdehemoglobinaglicosiladaydiferenciaenelgastoensaluddepacientesdiabeticosunestudioeconometrico AT ramirezjorge nivelesdehemoglobinaglicosiladaydiferenciaenelgastoensaluddepacientesdiabeticosunestudioeconometrico
_version_	1718436765249830912

Niveles de hemoglobina glicosilada y diferencia en el gasto en salud de pacientes diabéticos: un estudio econométrico

Ejemplares similares